trial
as of 2026-07-01Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
NCTId NCT06229210
at a glance
Phase 3 · Recruiting
Enrollment 500 (estimated)
Sponsored by Intra-Cellular Therapies, Inc.
Primary completion 2027-12
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 3
Status
Recruiting
Enrollment
500 (estimated)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2024-01-25
Primary completion
2027-12
Eligibility
ALL · 5 Years · 17 Years
Interventions & indications
Sponsors
Intra-Cellular Therapies, Inc.Lead Sponsor
Sites
50 total
Phoenix, United StatesLittle Rock, United StatesAnaheim, United StatesColton, United StatesGarden Grove, United StatesLong Beach, United StatesRedlands, United StatesSan Diego, United StatesWest Covina, United StatesColorado Springs, United StatesGainesville, United StatesHialeah, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
500
Phase
PHASE3
Primary Completion Date
2027-12
Status
RECRUITING
relationships
The graph out of here
drug
lead_sponsor
indication